Actively Recruiting
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Led by Vanderbilt University Medical Center · Updated on 2026-01-22
50
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
Sponsors
V
Vanderbilt University Medical Center
Lead Sponsor
A
American Heart Association
Collaborating Sponsor
AI-Summary
What this Trial Is About
Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia. Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection. The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo
CONDITIONS
Official Title
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years and older
- Diagnosed with Long COVID defined by symptoms lasting more than three months after SARS-CoV-2 infection
- Diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) with chronic symptoms over 3 months
- Orthostatic tachycardia defined as heart rate increase over 30 bpm upon standing or exceeding 120 bpm within 10 minutes, or over 40 bpm increase or heart rate over 130 bpm for ages 18 to 21
- Confirmation of POTS diagnosis based on orthostatic vital signs prior to enrollment
- Documented SARS-CoV-2 infection at least 3 months prior by clinical, epidemiological, antigen test, or nucleic acid test criteria
- Clinical confirmation by healthcare provider in medical records
You will not qualify if you...
- Active acute SARS-CoV-2 infection within 4 weeks from onset
- Moderate or severe immunocompromised status
- History of cardiovascular disease including atrioventricular block, myocardial infarction, angina, heart failure, pacemaker, stroke, or transient ischemic attack within 6 months
- Uncontrolled hypertension with blood pressure over 140/90 despite treatment
- Type 1 or type 2 diabetes mellitus
- Impaired liver function with AST or ALT greater than 1.5 times the upper limit, or bilirubin 1.5 mg/dl or higher
- Impaired kidney function with estimated glomerular filtration rate below 60 mL/min/1.73 m2
- Anemia with hemoglobin less than 10 g/dl
- Pregnant or breastfeeding women
- Known autoimmune disease or use of steroids or other immunotherapies
- Inability to provide informed consent
- Allergy or sensitivity to study medication components
- Contraindications to study interventions
- Use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donepezil)
- Aspirin allergy
- Use of monoamine oxidase inhibitors (MAO-I)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cyndya Shibao
Nashville, Tennessee, United States, 37027
Actively Recruiting
Research Team
M
Marwa Mohamed, PhD
CONTACT
C
Cyndya Shibao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here